ESC 365 - Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

ESC Premium Access

Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

Session: Highlights from the New England Journal of Medicine: editors’ choice

Topic: European Society of Cardiology

Speaker: Professor C. Rapezzi (Ferrara, IT)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

28 presentations

1 follower

2 more presentations in this session

Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).

Speaker: Professor J. Mcneil (Melbourne, AU)

Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.

Speaker: Doctor M. Mack (Dallas, US)

Access the full session

Highlights from the New England Journal of Medicine: editors’ choice

Speakers: Professor C. Rapezzi, Professor J. Mcneil, Doctor M. Mack

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Related content

Open Access

Mode of intervention in mitral regurgitation.

28 August 2021

Open Access

Timing and indication of intervention in asymptomatic patients with valvular heart disease.

28 August 2021

ESC Premium Access

A comprehensive guide to risk stratification for sudden cardiac death in hypertrophic cardiomyopathy.

27 August 2021

ESC 365 is supported by